Join David Craig, Co-Founder, President, and CEO of Sarcomatrix Therapeutics, for a masterclass on disrupting the traditional pharmaceutical development playbook. Rare neuromuscular diseases have long been underserved—not due to a lack of scientific potential, but because legacy pharma cost structures fail to scale to small patient populations. Drawing on 30 years of drug development leadership at industry giants like Amgen, Gilead, and Portola, David shares how Sarcomatrix is testing a lean, hyper-disciplined operating model to translate university research into clinical-grade therapeutics without the typical overhead waste.

🎯 Insights You’ll Learn:

The Personal & Professional Origin: How a personal family connection to genetic muscle disease inspired David to bridge the gap between academic research and commercial drug discover ...